Xenon Pharmaceuticals Announces Pricing of Initial Public Offering

BURNABY, British ColumbiaNov. 4, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 4,000,000 of its common shares at a price to the public of $9.00 per share. In addition, Xenon Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares at the initial public offering price. The common shares are expected to begin trading on the NASDAQ Global Market on November 5, 2014 under the symbol "XENE."  

Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. is acting as co-manager.

A registration statement relating to this offering of common shares has been declared effective by the Securities and Exchange Commission on November 4, 2014, and the offering is also qualified by a prospectus filed in each of British ColumbiaAlbertaand Ontario.

The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Jefferies LLCEquity Syndicate Prospectus Department520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at [email protected]; or Wells Fargo Securities, LLCEquity Syndicate Department375 Park AvenueNew York, NY 10152, or by telephone at (800) 326-5897, or by email at[email protected], and a Canadian prospectus, a copy of which may be obtained from Canaccord Genuity Corp. Attn: Syndication, 161 Bay Street, Suite 3000 Toronto, ON M5J 2S1, or by telephone at (416) 869-7398 or by email at[email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT: Ian Mortimer
         Chief Financial Officer
         Xenon Pharmaceuticals Inc.
         Phone: 604.484.3300
         Email: [email protected]

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.